Uncertain translation, uncertain benefit and uncertain risk: Ethical challenges facing first-in-human trials of induced pluripotent stem (ips) cells
Bioethics 27 (2):89-96 (2013)
AbstractThe discovery of induced pluripotent stem (iPS) cells in 2006 was heralded as a major breakthrough in stem cell research. Since then, progress in iPS cell technology has paved the way towards clinical application, particularly cell replacement therapy, which has refueled debate on the ethics of stem cell research. However, much of the discourse has focused on questions of moral status and potentiality, overlooking the ethical issues which are introduced by the clinical testing of iPS cell replacement therapy. First-in-human trials, in particular, raise a number of ethical concerns including informed consent, subject recruitment and harm minimisation as well as the inherent uncertainty and risks which are involved in testing medical procedures on humans for the first time. These issues, while a feature of any human research, become more complex in the case of iPS cell therapy, given the seriousness of the potential risks, the unreliability of available animal models, the vulnerability of the target patient group, and the high stakes of such an intensely public area of science. Our paper will present a detailed case study of iPS cell replacement therapy for Parkinson's disease to highlight these broader ethical and epistemological concerns. If we accept that iPS cell technology is fraught with challenges which go far beyond merely refuting the potentiality of the stem cell line, we conclude that iPS cell research should not replace, but proceed alongside embryonic and adult somatic stem cell research to promote cross-fertilisation of knowledge and better clinical outcomes
Similar books and articles
Moral Complicity in Induced Pluripotent Stem Cell Research.Mark T. Brown - 2009 - Kennedy Institute of Ethics Journal 19 (1):pp. 1-22.
No Ethical Bypass of Moral Status in Stem Cell Research.Mark Brown - 2013 - Bioethics 27 (1):12-19.
Stem Cell Research: An Ethical Evaluation of Policy Options.Nikolaus Knoepffler - 2004 - Kennedy Institute of Ethics Journal 14 (1):55-74.
The Ethics of Moral Compromise for Stem Cell Research Policy.Zubin Master & G. K. D. Crozier - 2012 - Health Care Analysis 20 (1):50-65.
Safety Issues In Cell-Based Intervention Trials.Liza Dawson, Alison S. Bateman-House, Dawn Mueller Agnew, Hilary Bok, Dan W. Brock, Aravinda Chakravarti, Mark Greene, Patricia King, Stephen J. O'Brien, David H. Sachs, Kathryn E. Schill, Andrew Siegel & Davor Solter - 2003 - Fertility and Sterility 80 (5):1077-1085.
The Ethics and Politics of Small Sacrifices in Stem Cell Research.Glenn McGee & Arthur L. Caplan - 1999 - Kennedy Institute of Ethics Journal 9 (2):151-158.
International Society for Stem Cell Research (ISSCR) Guidelines for the Conduct of Human Embryonic Stem Cell Research (December 2006).Bernard Dickens - unknown
Developments in Stem Cell Research and Therapeutic Cloning: Islamic Ethical Positions, a Review.Hossam E. Fadel - 2012 - Bioethics 26 (3):128-135.
Allowing Innovative Stem Cell-Based Therapies Outside of Clinical Trials: Ethical and Policy Challenges.Insoo Hyun - 2010 - Journal of Law, Medicine and Ethics 38 (2):277-285.
Stem Cell Research as Innovation: Expanding the Ethical and Policy Conversation.Rebecca Dresser - 2010 - Journal of Law, Medicine and Ethics 38 (2):332-341.
Ethical Issues in Human Embryonic Stem Cell Research.Philip J. Nickel - 2008 - In Kristen Renwick Monroe, Ronald B. Miller & Jerome Tobis (eds.), Fundamentals of the Stem Cell Debate: The Scientific, Religious, Ethical & Political Issues. University of California Press.
The Race Toward 'Ethically Universally Acceptable' Human Pluripotent (Embryonic-Like) Stem Cells: Only a Problem of Sources?Demetrio Neri - 2011 - Bioethics 25 (5):260-266.
Broadening the Scope of Debates Around Stem Cell Research.Tamra Lysaght & Alastair V. Campbell - 2013 - Bioethics 27 (5):251-256.
Resolving Ethical Issues in Stem Cell Clinical Trials: The Example of Parkinson Disease.Bernard Lo & Lindsay Parham - 2010 - Journal of Law, Medicine and Ethics 38 (2):257-266.
Added to PP
Historical graph of downloads
Citations of this work
“I Want to Do It, But I Want to Make Sure That I Do It Right.” Views of Patients with Parkinson’s Disease Regarding Early Stem Cell Clinical Trial Participation.Inmaculada de Melo-Martín, Michael Holtzman & Katrina S. Hacker - 2020 - AJOB Empirical Bioethics 11 (3):160-171.
Participant Selection for Preventive Regenerative Medicine Trials: Ethical Challenges of Selecting Individuals at Risk.Sophie L. Niemansburg, Michelle G. J. L. Habets, Wouter J. A. Dhert, Johannes J. M. van Delden & Annelien L. Bredenoord - 2015 - Journal of Medical Ethics 41 (11):914-916.
References found in this work
No references found.